Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Frontier Pharma: Hematological Disorders - Iron Regulators and Immune Response Targeted Programs Within Anemias & Other Red Blood Cell Disorders Hold Potential to Transform Therapy Area - Research and Markets

Research and Markets
Posted on: 04 Sep 17

The "Frontier Pharma: Hematological Disorders - Iron Regulators and Immune Response Targeted Programs Within Anemias and other Red Blood Cell Disorders Hold Potential to Transform Therapy Area with Significant Unmet Need" report has been added to Research and Markets' offering.

Globally prevalent disorders such as anemias, of which the most common form - iron deficiency anemia - is estimated to affect over 13% of the world's population, represent significant investment opportunities due to the number of patients eligible for treatment. Although some forms of iron deficiency anemia are treatable with iron supplementation, other forms are hereditary in their etiology, such as iron malabsorption, and therefore require an alternative treatment approach to improve patient care. The therapy area also contains rare disorders of much lower prevalence, such as paroxysmal nocturnal hemoglobinuria, which is classified as an orphan disease and has no currently marketed treatment options.

Historically the hematological disorders therapy area has suffered from a lack of funding for research, leading to a low number of treatment options. However, first-in-class pipeline innovation is promising and 92 of 327 pipeline programs (28%) with a disclosed molecular target are first-in-class. Investment in first-in-class development is particularly important within hematological disorders as it holds the potential of achieving clinical breakthroughs through radical pharmaceutical innovation. A successful marketed product has the potential to gain a large market share due to the significant level of unmet need with regard to effective marketed treatment options.

The report has been designed to identify innovative pipeline programs across a therapy area, with a focus on indications with high R&D activity, strong innovation, a competitive commercial landscape and high levels of deal activity. Monitoring innovative new product developments is becoming increasingly important, not just for companies looking to acquire technologies, products or smaller companies that are seeking strategic partnerships, but also as a vital element of competitive intelligence for all market participants.

Key Topics Covered:

1 Table of Contents

2 Executive Summary

3 The Case for Innovation in the Hematological Disorders Market

4 Clinical and Commercial Landscape

5 Pipeline Landscape Assessment

6 Hematological Disorders Signaling Network and Innovation Alignment

7 First-in-Class Target Evaluation

8 Deals and Strategic Consolidations

9 Appendix

For more information about this report visit

View source version on

Business Wire

Last updated on: 04/09/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.